Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 10;6(9):2927-2931.
doi: 10.1182/bloodadvances.2021006350.

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera

Paola Guglielmelli  1 , Giacomo Coltro  1 , Francesco Mannelli  1 , Giada Rotunno  1 , Giuseppe G Loscocco  1 , Carmela Mannarelli  1 , Chiara Maccari  1 , Chiara Paoli  1 , Simone Romagnoli  1 , Niccolò Bartalucci  1 , Alessandro M Vannucchi  1
Affiliations

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera

Paola Guglielmelli et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Genetic mutations frequency and Kaplan-Meier estimates of overall survival. (A) Bar graph reporting the frequency of driver and nondriver genetic mutations among patients with PMF and SMF. (B-D) Kaplan-Meier estimates of overall survival (OS) in the entire series of patients with MF (B) or those with PMF (C) or SMF (D) separately, according to the 4-tier genomic classification (NGS) proposed by Luque Paz et al. (E-F) Kaplan-Meier estimates of OS in high-risk patients with PMF (E) and SMF (F) by the presence or absence of ASXL1mut. *P < .1, **P < .001, ****P < .0001. DM, double mutated; TN, triple negative; WT, wild type.
Figure 2.
Figure 2.
Performance of prognostic scoring systems. (A) Comparison of the prognostic performance among standard prognostic scoring systems (DIPSS for PMF and MYSEC-PM for SMF), their combinations with molecular scores (HMR and NGS), and novel integrated clinical-molecular score systems (MIPSS70 and MIPSS70plus version 2.0). For the purpose of the study, the HMR model included 3 genomic categories: patients with no mutations in HMR genes (ie, ASXL1, EZH2, SRSF2, IDH1 and IDH2, and U2AF1), patients with 1 HMR mutation, and patients with ≥2 HMR mutations. (B-C) Brier score for prediction of death measured over time for standard and integrated prognostic scoring systems in PMF (B) and SMF (C). (D-E) Time-dependent area under the curve (AUC) for prediction of death for standard and integrated prognostic scoring systems in PMF (D) and SMF (E).
See this image and copyright information in PMC

References

    1. Vannucchi AM, Lasho TL, Guglielmelli P, et al. . Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861-1869. - PubMed
    1. Tefferi A, Lasho TL, Finke CM, et al. . Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1(2):105-111. - PMC - PubMed
    1. Rotunno G, Pacilli A, Artusi V, et al. . Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group. Am J Hematol. 2016;91(7):681-686. - PubMed
    1. Tefferi A, Finke CM, Lasho TL, et al. . U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia. 2018;32(10):2274-2278. - PMC - PubMed
    1. Luque Paz D, Riou J, Verger E, et al. . Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Adv. 2021;5(5):1442-1451. - PMC - PubMed